过氧化物酶体增殖物激活受体γ与脓毒症的相关研究进展  

The Research Progress of PPARγ in Sepsis

作　　者：莫桂熙[1] 张良清[1] 

机构地区：[1]广东医学院附属医院麻醉科,广东湛江524001

出　　处：《医学综述》2015年第2期224-226,共3页Medical Recapitulate

摘　　要：过氧化物酶体增殖物激活受体γ(PPARγ)通过多种机制参与脓毒症的调控,影响脓毒症的进展。一方面,PPARγ阻止转录因子及其辅助因子与一氧化氮合酶、肿瘤坏死因子α、白细胞介素1β、诱导型环氧合酶2等炎症相关因子启动子上的相应位点结合,进而抑制靶基因的表达。因此,其在脓毒症的高炎性反应阶段发挥明显的抗炎作用,改善了部分脓毒症患者的预后。另一方面,PPARγ能诱导免疫细胞的凋亡和中性粒细胞的麻痹,这在高炎性反应阶段可能是有利的,但是在抗炎性反应为主的脓毒症后期,则可能会增加二次感染的机会,导致病情恶化。PPARγ在脓毒症中的作用目前仍存在争议,尚有待进一步的研究阐明。Peroxisome proliferator-activated receptor γ（ PPARγ） involves in the regulation of sepsis through a variety of mechanisms,affecting the progress of sepsis. On one hand,PPARγ inhibits inflammatory gene expression,such as those for inducible nitric oxide synthase,TNF-α,IL-1β,or inducible cyclooxygenase-2,by inhibiting transcription factors and their cofactors,thus preventing them from binding to their cognate binding sites in the promoters of target genes. Therefore,in the hyper-inflammatory phase of sepsis,PPARγ＇s significant anti-inflammatory role improves the prognosis of patients with sepsis. On the other hand,PPARγ provokes apoptosis and neutrophil paralysis,which might be helpful in the hyper-inflammatory phase of sepsis. However,during the anti-inflammatory phase,it may increase the chance of a second infection,thus cause worse outcome. Therefore the role of PPARγ in sepsis is still controversial,awaiting further studies to clarify.

关 键 词：过氧化物酶体增殖物激活受体 脓毒症 脓毒症综合征 细胞凋亡 

分 类 号：R631.2[医药卫生—外科学]